WINT stock forecast
Our latest prediction for Windtree Therapeutics Inc's stock price was made on the Nov. 19, 2021 when the stock price was at 1.56$.
In the short term (2weeks), WINT's stock price should outperform the market by 3.31%. During that period the price should oscillate between -10.35% and +17.85%.
In the medium term (3months), WINT's stock price should outperform the market by 1.79%. During that period the price should oscillate between -41.06% and +52.47%.Get email alerts
Create a solid portfolio with WINT
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.74$ per share.
The book value per share is -8.31$
Three months stock forecastNov. 19, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|